<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>#022: A Map of Mitochondria Longevity Companies (PART 1) - Hex Index</title>
  <link rel="stylesheet" href="../../styles.css">
</head>
<body class="reading-mode">
  <header class="reading-header">
    <a href="../../index.html" class="back-link">&larr; Back to Library</a>
  </header>
  <main class="reading-content">
    
    <article class="article-page">
      <header class="article-header">
        <h1>#022: A Map of Mitochondria Longevity Companies (PART 1)</h1>
        <div class="article-meta">
          <span class="author">By Nathan Cheng</span>
          <span class="separator">&middot;</span>
          <a href="../../publication/longevitymarketcap/index.html" class="publication">
            Longevity Marketcap
          </a>
          <span class="separator">&middot;</span><time>Mar 3, 2021</time>
          <span class="separator">&middot;</span>
          <span class="read-time">48 min read</span>
        </div>
      </header>

      

      <div class="article-excerpt">
        <h1><strong>üì°</strong>In this edition of Longevity Marketcap Telemetry</h1><ol><li><p>Last Week in Longevity</p></li><li><p>Longevity Futures</p></li><li><p>Longevity Jobs</p></li><li><p>A Tour of All Mitochondria Longevity Companies</p></li><li><p>Tweet of the Week</p></li></ol><div><hr></div><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!rjWh!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fbucketeer-e05bbc84-baa3-437e-9518-adb32be77984.s3.amazonaws.com%2Fpublic%2Fimages%2F2ea6c9a9-fd11-4033-be1b-d7a57f269c72_1508x860.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!rjWh!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fbucketeer-e05bbc84-baa3-437e-9518-adb32be77984.s3.amazonaws.com%2Fpublic%2Fimages%2F2ea6c9a9-fd11-4033-be1b-d7a57f269c72_1508x860.png 424w, https://substackcdn.com/image/fetch/$s_!rjWh!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fbucketeer-e05bbc84-baa3-437e-9518-adb32be77984.s3.amazonaws.com%2Fpublic%2Fimages%2F2ea6c9a9-fd11-4033-be1b-d7a57f269c72_1508x860.png 848w, https://substackcdn.com/image/fetch/$s_!rjWh!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fbucketeer-e05bbc84-baa3-437e-9518-adb32be77984.s3.amazonaws.com%2Fpublic%2Fimages%2F2ea6c9a9-fd11-4033-be1b-d7a57f269c72_1508x860.png 1272w, https://substackcdn.com/image/fetch/$s_!rjWh!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fbucketeer-e05bbc84-baa3-437e-9518-adb32be77984.s3.amazonaws.com%2Fpublic%2Fimages%2F2ea6c9a9-fd11-4033-be1b-d7a57f269c72_1508x860.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!rjWh!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fbucketeer-e05bbc84-baa3-437e-9518-adb32be77984.s3.amazonaws.com%2Fpublic%2Fimages%2F2ea6c9a9-fd11-4033-be1b-d7a57f269c72_1508x860.png" width="602" height="343.1730769230769" data-attrs="{&quot;src&quot;:&quot;https://bucketeer-e05bbc84-baa3-437e-9518-adb32be77984.s3.amazonaws.com/public/images/2ea6c9a9-fd11-4033-be1b-d7a57f269c72_1508x860.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:830,&quot;width&quot;:1456,&quot;resizeWidth&quot;:602,&quot;bytes&quot;:null,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:null,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:true,&quot;internalRedirect&quot;:null,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!rjWh!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fbucketeer-e05bbc84-baa3-437e-9518-adb32be77984.s3.amazonaws.com%2Fpublic%2Fimages%2F2ea6c9a9-fd11-4033-be1b-d7a57f269c72_1508x860.png 424w, https://substackcdn.com/image/fetch/$s_!rjWh!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fbucketeer-e05bbc84-baa3-437e-9518-adb32be77984.s3.amazonaws.com%2Fpublic%2Fimages%2F2ea6c9a9-fd11-4033-be1b-d7a57f269c72_1508x860.png 848w, https://substackcdn.com/image/fetch/$s_!rjWh!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fbucketeer-e05bbc84-baa3-437e-9518-adb32be77984.s3.amazonaws.com%2Fpublic%2Fimages%2F2ea6c9a9-fd11-4033-be1b-d7a57f269c72_1508x860.png 1272w, https://substackcdn.com/image/fetch/$s_!rjWh!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fbucketeer-e05bbc84-baa3-437e-9518-adb32be77984.s3.amazonaws.com%2Fpublic%2Fimages%2F2ea6c9a9-fd11-4033-be1b-d7a57f269c72_1508x860.png 1456w" sizes="100vw" fetchpriority="high"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"></div></div></div></a></figure></div><p><strong>Dear Longevity Nerds: </strong>üéâüéâüéâWe have reached 925 subscribers -- <strong>still doubling every ~7 weeks</strong>. The movement is growing stronger and stronger every day thanks to early adopters like you! Spread the word about longevity biotechnology and we can solve aging <strong>even faster</strong>.</p><p><em><strong>Note</strong>: Sorry this week‚Äôs newsletter is a bit long (14,000+ words, R.I.P. your inbox). Future newsletters will be much shorter now that this particular topic is out of the way.&nbsp;</em></p><p><em><strong>Edit: </strong>I broke Substack ‚Äî I am forced to split the newsletter into Part 1 and <a href="https://sub.longevitymarketcap.com/p/022-mitochondria-longevity-companies-448">Part 2.</a> </em></p><p>-NATHAN</p><p><em><strong>Disclaimer: </strong>None of this should be taken as financial advice. This information is for educational purposes only.&nbsp;</em></p><div><hr></div><h2><strong>üìù</strong>Last Week in Longevity</h2><ul><li><p><strong><a href="https://bioagelabs.com/BGE-117_Phase_2_Initiation_Press_Release.pdf">BioAge enters the clinic with Phase 2a trial.</a> </strong>Kristen Fortney‚Äôs a16z-backed AI/ML drug discovery startup announced it had initiated a Phase 2a clinical trial of BGE-117 to treat unexplained adult anemia (UAA), an age-related disease that affects 10% of those over 65 years of age. Topline data is expected in H1 2022.&nbsp;</p><p>BGE-117 is a Hypoxia-Inducible Factor (HIF) activator licensed from Taisho Pharmaceuticals that has been shown to increase Hb and EPO levels in humans without UAA in Phase 1 trials. BGE-117 may also have benefits that extend to broader aging: BioAge mined proprietary biobanks to determine that individuals that had higher levels of HIF were much more likely to live past 85. A success here would not only be huge for the longevity industry but also AI/ML drug discovery as a whole. <a href="https://twitter.com/realnathancheng/status/1365099977429688324?s=21">Truly exciting.</a></p></li><li><p><strong><a href="https://www.reuters.com/article/us-biotech-spac-exclusive-idUSKBN2AH2D3">Christian Angermayer‚Äôs Apeiron SPAC -- David Sinclair and Peter Attia to be co-chairmen</a>. </strong>Angermayer‚Äôs <strong>Frontier Acquisition Corp</strong>, a blank-check SPAC company, will list as early as March. Angermayer is also a founder and financier of <a href="https://www.prnewswire.com/news-releases/cambrian-biopharma-announces-60m-in-financing-to-develop-a-pipeline-of-companies-and-therapeutics-to-treat-diseases-of-aging-coupled-with-a-unique-operational-strategy-301224991.html">Cambrian Biopharma</a>, a multi-portfolio longevity biotech company that came out of stealth this month. Peter Attia, a medical doctor with a longevity practice and popular podcast, is well known in the longevity/biohacking space (as is David Sinclair). I‚Äôm guessing this is a nutraceuticals or wellness play and not a deep biotech acquisition.</p></li><li><p><strong><a href="https://investors.chromadex.com/news/news-details/2021/New-Phase-3-Clinical-Study-Finds-Nutritional-Protocol-Including-Nicotinamide-Riboside-Accelerates-Recovery-in-Mild-to-Moderate-COVID-19-Patients/default.aspx">ChromaDex (NYSE:CDXC) stock surges over 100% on Phase 3 COVID recovery trials</a>. </strong>ChromaDex is the maker of TruNiagen, a nicotinamide riboside (NR) NAD+ boosting supplement. In a preprint posted on <a href="https://www.medrxiv.org/content/10.1101/2020.10.02.20202614v2">medrXiv</a>, </p></li></ul>...</source>
      </div>

      <div class="read-full-article">
        <a href="https://sub.longevitymarketcap.com/p/022-mitochondria-longevity-companies" class="read-button" target="_blank" rel="noopener">
          Read full article on Longevity Marketcap &rarr;
        </a>
        <p class="copyright-note">
          This excerpt is provided for preview purposes.
          Full article content is available on the original publication.
        </p>
      </div>
    </article>
  
  </main>
</body>
</html>